Genetic technology is known as the next technology that will change the world
.
In recent years, China has successively issued a series of policies such as the "14th Five-Year Plan") and the "14th Five-Year Plan for Bioeconomic Development" to support and encourage the development of biomedical and general health industries
.
With the development of sequencing technology, the improvement of people's living standards and the enhancement of health care awareness, the market prospect of gene technology will be very broad
.
According to data, the domestic gene sequencing market will be about 1.
59 billion US dollars in 2021, and will grow at a compound annual growth rate of 21.
6% by 2026, reaching about 4.
24 billion US dollars.
The market has great potential for development
.
In this context, relevant companies are increasing their layout on this track
.
Huada Gene announced on the morning of August 12 that the company plans to use its own funds not exceeding 1.
65 billion yuan to invest in the construction of the Huada Gene headquarters base project in the joint bid for the joint bid of J402-0349 in Yantian District
.
According to the project overview, the headquarters base project plans to build R&D office area, international exhibition area and other functional areas, integrating the global headquarters, R&D center, international life science exchange display and experience center, including headquarters office, teaching and training center, Technology research and development center, industrial development center and supporting dormitory
.
The total construction area occupied by the company is approximately 95,892.
75 square meters (including approximately 52,380.
88 square meters of biotechnology research and development buildings, approximately 39,372.
10 square meters of supporting dormitories, and approximately 4,139.
77 square meters of reduced area)
.
Regarding the purpose of this headquarters base project, the company stated that there is an industrial chain that is conducive to integrating genetic testing-related industries to achieve industrial scale effect and agglomeration effect
.
At the same time, after the company participates in the development and construction of this project, it can meet the needs of the company's future business development for operating sites, enhance the company's sustainable development capabilities, and provide necessary guarantees for the company's future development, which is conducive to the company's long-term development and is in line with the company's long-term development strategy
.
At the same time, BGI said that the project funds come from the company's own or self-raised funds, and will be gradually invested in stages according to the project construction progress
.
At present, the company's financial situation is relatively stable and its cash flow is relatively abundant.
This investment will not affect the company's normal operating activities, and will not have a significant adverse impact on the company's current and future financial conditions and operating results, nor will it harm the interests of the company and minority shareholders.
situation
.
According to the data, BGI is a science and technology service provider and precision medical service operator.
Its business has covered more than 100 countries and regions around the world, and it has cooperated with more than 2,000 scientific research institutions and more than 2,300 medical institutions across the country.
It provides research services and comprehensive solutions for precision medical testing for scientific research institutions, enterprises and institutions, medical institutions, social health organizations,
etc.
From the perspective of financial data, the 2021 financial report shows that BGI will achieve operating income of 6.
766 billion yuan in 2021, a year-on-year decrease of 19.
42%, and a net profit of 1.
4629 billion yuan, a year-on-year decrease of 30.
08%; the 2022 semi-annual report performance forecast shows that it is expected that the company In the first half of 2022, the net profit was 580 million yuan to 720 million yuan, a year-on-year decrease of 33.
7% to 46.
59%; the non-net profit after deduction was 510 million yuan to 680 million yuan, a year-on-year decrease of 33.
95% to 49.
98%
.
As of the first quarter of 2022, BGI's cash flow per share was -1.
629 yuan
.
![2,4,8,10-Tetraoxa-3,9-dithiaspiro[5.5]undecane, 3,3,9,9-tetraoxide](https://file.echemi.com/fileManage/upload/category/ac71ac0d-8ef6-11ec-89e5-fa163ed06441.png)
